Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 252-305-5 | CAS number: 34977-63-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Disodium 3(or 5)-[[4-[(7-amino-1-hydroxy-3-sulphonato-2-naphthyl)azo]-1-naphthyl]azo]salicylate
- EC Number:
- 252-305-5
- EC Name:
- Disodium 3(or 5)-[[4-[(7-amino-1-hydroxy-3-sulphonato-2-naphthyl)azo]-1-naphthyl]azo]salicylate
- Cas Number:
- 34977-63-4
- Molecular formula:
- C27H19N5O7S.2Na
- IUPAC Name:
- tetrasodium 3-[(1E)-2-{4-[(1E)-2-(7-amino-1-hydroxy-3-sulfonatonaphthalen-2-yl)diazen-1-yl]naphthalen-1-yl}diazen-1-yl]-2-hydroxybenzoate 5-[(1E)-2-{4-[(1E)-2-(7-amino-1-hydroxy-3-sulfonatonaphthalen-2-yl)diazen-1-yl]naphthalen-1-yl}diazen-1-yl]-2-hydroxybenzoate
- Reference substance name:
- Sodium chloride
- EC Number:
- 231-598-3
- EC Name:
- Sodium chloride
- Cas Number:
- 7647-14-5
- Molecular formula:
- ClNa
- IUPAC Name:
- sodium chloride
- Test material form:
- solid: particulate/powder
- Details on test material:
- Appearance: black powderTrade name: Saturn Black LNBatch No: 9013CAS No: 34977-63-4
Constituent 1
impurity 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- Balb/c
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS- Source: Breeding farm VELAZ, Unětice 139, 252 62, Czech Republic (RČH CZ 21760118)- Age at study initiation: 8 - 10 weeks- Weight at study initiation: 18.14 – 21.66 g (in pilot experiment 18.27 – 19.16 g)- Housing: in groups in macrolon cages with sterilized softwood shavings at monitored conditions, microbiologically defined background (according to internal SOP No.40)- Diet (e.g. ad libitum): pelleted standard diet for experimental animals ad libitum (Altromin, manufacturer: Altromin Spezialfutter GmbH & Co. KG, Germany). Microbiological control and content of nutrients is performed according internal SOP No. 72- Water (e.g. ad libitum): drinking tap water ad libitum (water quality corresponded to Regulation No. 252/2004 Czech Coll. Of Law)- Acclimation period: 28 daysENVIRONMENTAL CONDITIONS- Temperature: 22 ± 3 °C, permanently monitored- Humidity: 30 – 70 %, permanently monitored- Photoperiod: Light: 12 hours light/dark
Study design: in vivo (LLNA)
- Vehicle:
- other: DAE 433 – mixture of 40% dimethylacetamide, 30% acetone and 30% ethanol
- Concentration:
- 75% (w/v) - 750 mg/mL 7.5% (w/v) - 75 mg /mL0.75% (w/v) - 7.5 mg /mL
- No. of animals per dose:
- 3 animals per dose
- Details on study design:
- RELIABILITY CHECK For the demonstration of test efficiency a group of animals treated with a substance with proved positive effect is included in each test (positive effect = Stimulation Index SI ≥ 3). The substance DNCB (dinitrochlorobenzene, 0.5% (w/v) solution) was used as the positive control. A dose level for DNCB was determined during the verification of the method. The vehicle and dosage volume were the same as in treated groups. An application form was prepared on each day of administration by dissolving an appropriate amount of the positive control substance in the vehicle to obtain a concentration of 5 mg/mL. The solution was mixed for 5 minutes with a magnetic stirrer. PILOT EXPERIMENTThe test substance was administered to three animals to assess a possible systemic toxicity or high irritation of skin. One animal per dose group was used in pilot experiment.The pilot experiment was conducted under the conditions identical to the main study, except the assessment of lymph node proliferation. The appropriate suspensions of the test substance (75%, 7.5%, 0.75% w/v) was applied to three animals in volume 25 µl to the dorsum of each ear once a day morning for 3 consecutive days. The suspensions were prepared before the start of application by mixing on magnetic stirrer and then were still mixed during application. The application was performed very slowly by micropipette. The route of administration was the same as in the main study. Both ears of each mouse was observed for erythema and scored and subsequently ear thickness was measured using digital thickness gauge. Body weight was recorded before application and prior to termination (Day 6).According to the results of pilot experiment, the doses used in pilot experiment were chosen also for main study.MAIN STUDY ANIMAL CHECK-IN AND ALLOCATION TO GROUPSAnimals were subjected to a clinical examination (health check) shortly after arrival. No clinical changes were recorded. After acclimatization the animals have been randomly allocated to the dose groups and assigned animal numbers.APPLICATION The test substance was administered in the form of suspension in DAE 433.The volume of the application form was constant at all groups of animals - 25 l of the appropriate suspension to the dorsum of each ear once a day morning for 3 consecutive days. The application was performed very slowly by micropipette. Losses caused by draining from the ear must be minimized.The application forms of test substance (suspensions) were prepared immediately before administration.EXPERIMENTAL SCHEDULE - Day 1: Open application of 25μL (in the morning, by pipette) of appropriate suspension of the test substance, the vehicle alone or the positive control to the dorsum of each ear.- Day 2 and 3: The application procedure repeated as carried out on day 1.- Day 4 and 5: No treatment.- Day 6: The weight of animals was recorded. Injection 250 μL of phosphate-buffered saline (PBS) containing 7.76 e5 Bq of 3H-methyl thymidine into all test and control mice via the tail vein. Five hours later, the animals were killed. IN VIVO EXAMINATION- Mortality: During working hours the animals were checked for general health whenever other activities were performed – twice daily during the dosing period.- Clinical Observations: Clinical observation was performed according to internal SOP M/1 twice daily during the dosing period. All changes in behaviour and health condition of animals were recorded (e.g.: piloerection, lacrimation, appearance of skin, fur and mucous membrane, ataxia, tremors, and convulsions, aggressiveness, change in grooming activity, marked change in activity level changes in frequency and intensity of breathing such as dyspnoea, gasping, and rales etc). Efforts were made to characterize onset and duration of signs observed. During clinical observations the examination of skin irritation at application site was carried.- Body Weight: Individual body weights were measured using an electronic balance. Weighing was performed on the first day of treatment, before dosing, and on the day of necropsy before application of the radionuclide.POST MORTEM INVESTIGATIONS- Ears Weights: Immediately after scheduled humane kill of animals, the both ears were cut off and circular pieces from the apical area of each ear with a diameter of 8 mm (=0.5 cm2) were excised using a disposable punch and weighed together on analytical scales. - Incorporation of 3H-methyl Thymidine: The tissue of both of the lymph nodes was prepared by gentle mechanical disaggregation through 100 µm-mesh nylon gauze with concomitant pooling in 1 mL PSB (Phosphate Buffered Saline). The pairs of lymph nodes was analysed separately for each animal per group. Cells were washed twice with an excess of PBS and precipitated with 5% trichloroacetic acid (TCA) at 4°C for 18h. The pellets were re-suspended in 1 mL TCA and transferred to scintillation vials containing 10 mL of scintillation fluid. Incorporation of 3H-methyl thymidine was measured by β-scintillation counting (Beckmann LS 6500) as disintegrations per minute (DPM).DATA TREATMENT Mean values and standard deviations of ears weight and incorporation of 3H-methyl thymidine were computed for the test substance groups and for the positive as well as the vehicle control group. Stimulation index (for incorporation of 3H-methyl thymidine) was calculated by dividing mean values from exposed groups and the positive control group by the corresponding mean value of the vehicle control group. The index for the vehicle control group was set at 1 by definition.
- Positive control substance(s):
- other: 1-chloro-2,4-dinitrobenzene (CAS 97-00-7)
- Statistics:
- For statistical calculations the software Statgraphic Centurion (version XV, USA) was used. Statistical evaluation of measured parameters was performed at first by applying the non-parametric Kruskal-Wallis test for testing whether all group samples originate from the same distribution and then the non-parametric two-group Mann-Whitney rank test (probability level 0.05) for two-group comparisons.
Results and discussion
- Positive control results:
- See Table No. 1
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- 1.24
- Test group / Remarks:
- 0.75 %
- Key result
- Parameter:
- SI
- Value:
- 1.12
- Test group / Remarks:
- 7.5 %
- Key result
- Parameter:
- SI
- Value:
- 1.29
- Test group / Remarks:
- 75 %
- Cellular proliferation data / Observations:
- EC3 CALCULATIONCalculadted using least squares method; EC3 < 100 %.CLINICAL OBSERVATIONS:No animal died during the main study.Just reduction of body weight at the highest dose level but no other symptoms of toxicity were observed during the study. No erythema on application site was observed in all animals from the negative control group and all animals administered by the test substance.All animals in the positive control group showed symptoms caused by the application of positive control substance: hyperaemia of skin with well defined erythema on application site, clonospasm and increased response to stimuli. BODY WEIGHTSReduction of body weight was recorded in all animals at the highest dose level. One female has markedly reduced its weight (-2.11 g), in other females the reduction of body weight in tenths of grams was observed. Body weight increment was calculated from values of day 6 just before necropsy and day 1 before first application. Body weight increment was lower in all treated groups. The lowest increment was at the highest dose level.
Any other information on results incl. tables
Table No. 1: Results of Main Study
Group | negative control | positive control | 75% | 7.5% | 0.75% |
Activity (disintegrations per minute) | 132.20 | 2171.00 | 183.50 | 156.02 | 138.91 |
102.16 | 1687.32 | 132.56 | 160.75 | 143.53 | |
124.05 | 1196.97 | 154.70 | 161.18 | 185.24 | |
160.81 | 1868.14 | 131.65 | 127.82 | 120.22 | |
126.77 | 1544.89 | 229.71 | 120.80 | 213.10 | |
mean | 129.20 | 1693.66 | 166.42 | 145.31 | 160.20 |
standard deviation | 21.05 | 363.03 | 41.20 | 19.44 | 37.93 |
stimulation index | 1.00 | 13.11 | 1.29 | 1.12 | 1.24 |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the given test conditions the animals exposed to the test substance, Direct Black 51, does not elicit sensitising response in LLNA assay. Positive results in cell proliferation revealed that the test substance, Direct Black 51, could not be a contact allergen in mice. The test substance, Direct Black 51, provides negative sensitising response in LLNA assay.
- Executive summary:
The Local Lymph Node Assay (LLNA) with the incorporation of 3H-methyl thymidine radionuclide was used. The testing was conducted according to the Method B.42 – Skin Sensitisation: Local Lymph Node Assay, Council Regulation (EC) No.640/2012, published in O.J. L 193, 2012.
In this study the contact allergenic potential of Direct Black 51 was evaluated after topical application to female BALB/c mice. Mice were exposed to three concentrations of test substance suspended in vehicle DAE 433 (mixture of 40% dimethylacetamide, 30% acetone and 30% ethanol) for 3 consecutive days.
In pilot experiment the following concentrations of test substance in application forms were used: 75 %, 7.5 %, 0.75 % (w/v). According to the results of pilot experiment the same doses were confirmed for main study.
Primary proliferation of lymphocytes in the lymph node draining the site of application was evaluated using radioactive labelling of proliferating cells. The ratio of the proliferation in treated groups to that in vehicular controls, termed the Stimulation Index, was determined. The evaluation of ear weight was performed for elimination of false positive findings with certain skin irritants.
Comparison of Stimulation Indexes between treated groups and control vehicle group revealed that the test substance Direct Black 51 did not cause a significant increase in radioisotope incorporation into the DNA of dividing lymphocytes of animals treated by the test substance at all concentrations. The Stimulation Index of the all treated groups is < 3 and the value of disintegrations per minute (DPM) is not significantly increased compared to negative control.
The test substance caused slight increase of ear weight but no other indication of irritation to skin at all dose levels nevertheless statistical significance was observed at the highest dose level. With regard to the negative results of the study No.: 270/15/4AI: Direct Black 51- In vitro Skin Irritation Test (EpiDermTM Model); VUOS-CETA Report No. 15-323, 2015 it was not possible that irritation of skin was caused. Residues of the test substance on the ears were visible during whole study so it could cause this weight increase.
The animals exposed to the test substance at all doses showed no pathological and no other negative clinical symptoms of intoxication throughout the experiment. Only reduction of body weight was observed at the highest dose level.
The positive control item Dinitrochlorobenzene (DNCB) as a contact allergen (concentration 0.5% (w/v) elicited the expected reaction pattern with significant increase in Stimulation Index of cell proliferation and of ear weight. Appropriate performance of the assay in the test laboratory was then demonstrated.
Under the given test conditions, the test substance, Direct Black 51, provides negative sensitising response in LLNA assay. The SI at all dose levels was < 3.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.